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Abstract
Background: The predictive value of the serology to detection of IgM against the Mycobacterium leprae-derived
phenolic glycolipid-I/PGL-I to identify leprosy patients who are at higher risk of developing reactions remains
controversial. Whether baseline results of the ML Flow test can predict leprosy reactions was investigated among
a cohort of patients enrolled in The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil
(U-MDT/CT-BR).
Methods: This was a descriptive study focusing on the main clinical manifestations of leprosy patients enrolled
in the U-MDT/CT-BR from March 2007 to February 2012 at two Brazilian leprosy reference centers. For research
purposes, 753 leprosy patients were categorized according to a modified Ridley-Jopling (R&J) classification and
according to the development of leprosy reactions (reversal reaction/RR and erythema nodosum leprosum/ENL),
and whether they had a positive or negative bacillary index/BI.
Results: More than half of the patients (55.5 %) reported leprosy reaction: 18.3 % (138/753) had a RR and 5.4 %
(41/753) had ENL. Leprosy reactions were more frequent in the first year following diagnosis, as seen in 27 %
(205/753) of patients, while 19 % (142/753) developed reactions during subsequent follow-up. Similar frequencies
of leprosy reactions and other clinical manifestations were observed in paucibacillary (PB) and multibacillary (MB)
leprosy patients treated with U-MDT and regular MDT (R-MDT) (P = 0.43 and P = 0.61, respectively). Compared
with PB patients, leprosy reactions were significantly more frequent in MB patients with a high BI, and more
patients developed RR than ENL. However, RR and neuritis were also reported in patients with a negative BI.
At baseline, the highest rate of ML Flow positivity was observed in patients with a positive BI, especially those who
developed ENL, followed by patients who had neuritis and RR. Among reaction-free patients, 81.9 % were ML Flow
positive, however, the differences were not statistically significant compared to reactional patients (P = 0.45).
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Conclusions: MB and PB patients treated with R-MDT and U-MDT showed similar frequencies of RR and other clinical
manifestations. Positive ML Flow tests were associated with MB leprosy and BI positivity. However, ML Flow test results
at baseline showed limited sensitivity and specificity for predicting the development of leprosy reactions.
Keywords: Leprosy, Leprosy reactions, Bacillary index, Phenolic glycolipid-I, Clinical trial, ML Flow test, U-MDT/CT-BR,
Brazil
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Background
Leprosy, a complex chronic infectious disease caused by
Mycobacterium leprae, primarily affects the skin and
peripheral nerves and has a great potential to cause dis-
ability and irreversible deformities. Leprosy presents as a
spectrum of manifestations: lepromatous leprosy (LL) is
characterized by a high bacillary index, weak M. leprae-
specific cell-mediated immunity (CMI), and high antibody
titers. At the other extreme, tuberculoid (TT) patients
have a low bacillary index, strong M. leprae-specific CMI,
and weak antibody production. Immunologically unstable
borderline tuberculoid (BT), borderline lepromatous (BL),
and borderline-borderline (BB) forms lie in the middle of
the spectrum combining features of both LL and TT
forms [1].
During the chronic phase of leprosy, before diagno-
sis, during or after multidrug therapy (MDT), acute
immune-inflammatory episodes, known as type 1 reac-
tions or reversal reaction (RR) and type 2 reactions
represented mainly by erythema nodosum leprosum
(ENL), can lead to irreversible nerve damage [2, 3].
Moreover, neuritis characterized by intense spontan-
eous nerve pain is often associated with leprosy reac-
tions, but can also occur without any cutaneous
involvement [4]. Inappropriate therapeutic manage-
ment of neuritis may result in permanent nerve func-
tion impairment [5, 6].
The World Health Organization (WHO) has been
recommending MDT since 1981 [7]. Later, in 1988 a
clinical classification based on the number of skin le-
sions was used to define two different MDT regimens
[8] for either paucibacillary (PB) patients presenting up
to five skin lesions or for multibacillary (MB) patients
presenting more than five skin lesions. Multibacillary
leprosy patients are prescribed 12 supervised monthly
doses of rifampicin, dapsone, and clofazimine, plus self-
administered daily doses of dapsone and clofazimine.
Meanwhile, PB leprosy patients are treated with six su-
pervised monthly doses of rifampicin and dapsone, plus
self-administered daily doses of dapsone [7].
In 2007, an open-label, randomized clinical trial
was conducted to compare regular MDT (R-MDT),
as proposed by the WHO, and a uniform MDT (U-
MDT) regimen consisting of six doses of rifampin,
dapsone, and clofazimine for all leprosy patients (PB
and MB) despite of their classification based on the
number of lesions. The trial named the Clinical Trial
for Uniform Multidrug Therapy Regimen for Leprosy
Patients in Brazil (U-MDT/CT-BR) recruited leprosy
patients in two Brazilian endemic sites which remain
under clinical follow-up. Up until now, the total
person-time observed is 780 930 person-days, i.e. 2
139.5 person-years, with a maximum of 6.66 years of
follow-up [9].
Serology to detect immunoglobulin M (IgM) anti-
bodies against the M. leprae-derived phenolic
glycolipid-I (PGL-I) has been widely evaluated for lep-
rosy classification, including its simple and rapid
immunochromatographic ML Flow test which detects
IgM to PGL-I in 10 min [10]. Studies have shown that
the results of anti-PGL-I serology reflect the bacillary
index (BI) of leprosy patients, with MB patients show-
ing a high positivity rate (70 %–90 %) and PB patients
showing low seropositivity (15 %–40 %) [11–13]. Con-
flicting data have been reported about the predictive
value of anti-PGL-I serology for identifying patients
who are at a higher risk of developing leprosy reactions.
High levels of anti-PGL-I antibodies at diagnosis or
after treatment have been associated with a higher risk
of developing leprosy reactions [14–17], however, other
studies have shown similar anti-PGL-I levels among
reactional and reaction-free patients [18–20]. There-
fore, whether anti PGL-I serology can be used to iden-
tify patients at risk of developing leprosy reactions
remains unknown.
It is important to identify the risk factors for de-
veloping leprosy reactions in order to establish pre-
ventive strategies for reducing irreversible nerve
damage and sequelae [21]. The present study de-
scribes the main clinical manifestations including
leprosy reactions in a cohort of patients enrolled in
the U-MDT/CT-BR. In addition, the baseline results
of the ML Flow test for predicting the development
of leprosy reactions observed during follow-up were
evaluated.
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Methods
Study population
This was a descriptive study focusing on the main clin-
ical manifestations of leprosy patients enrolled in the
U-MDT/CT-BR from March 2007 to February 2012 at
two Brazilian leprosy reference centers: Dona Libânia
(Fortaleza, Ceará state, northeast region) and Alfredo
da Matta (Manaus, Amazonas state, north region),
according to previously described rationale and study
design [22].
Briefly, for the U-MDT/CT-BR study, following the
WHO operational classification [8], patients were
randomized into four groups: PB patients treated with
U-MDT, PB patients treated with R-MDT, MB patients
treated with U-MDT, and MB patients treated with R-
MDT. In the R-MDT cohort, MB patients with six or
more lesions were treated with 12 supervised monthly
doses of rifampicin, dapsone, and clofazimine, plus daily
self-administered doses of dapsone and clofazimine,
while PB patients presenting five or fewer lesions re-
ceived six supervised monthly doses of rifampicin and
dapsone, plus daily self-administered doses of dapsone
[23]. In the U-MDT cohort, six supervised monthly
doses of rifampicin, dapsone, and clofazimine, plus daily
self-administered doses of dapsone and clofazimine were
prescribed for both PB and MB patients.
For research purposes, patients were also categorized
according to a modified Ridley-Jopling (R&J) classifica-
tion system taking into account clinical features, histo-
pathological results of skin biopsies, and the BI on slit
skin smear; Mitsuda tests and BI of the skin biopsy were
not performed. This modified R&J classification taking
into account the development of reactions was used to
write this paper.
Our study group included 753 out of 859 patients
enrolled in the U-MDT/CT-BR; 12.3 % (106/859) of
patients were excluded due to: incomplete treatment
(n = 9), histopathological diagnosis not compatible
with leprosy (n = 3), patients requested to leave the
study (n = 8), death (n = 19), transfer of patients to
other sites (n = 9), patients lost to follow-up (n = 12),
adverse drug reactions (n = 25), other concomitant ill-
nesses (n = 5), leprosy relapse (n = 1), or other reasons
(n = 15). The patients’ clinical information was ob-
tained from the case report form, at baseline, and dur-
ing follow-up (from March 2007 to September 2013).
This included a monthly medical visit in the first year
and a yearly medical visit in the following 6 years;
clinical monitoring is still taking place. As part of
protocol, at enrollment, all patients were advised
about the signs and symptoms of leprosy reactions
and nerve function impairments, and advised to im-
mediately return to the clinic in case any abnormality
occurred.
Case definitions for leprosy reactions and neuritis
A RR was defined as an acute inflammation of pre-
existing cutaneous lesions with or without the appear-
ance of new lesions. The clinical diagnosis of ENL was
based on the acute appearance of erythematous nodular
skin lesions, tender to touch or painful in the absence of
external stimuli, accompanied by fever with or without
peripheral nerve pain and dysfunction. Neuritis was
defined as spontaneous nerve pain or by the presence of
thickened nerve trunks associated with loss of sensation
and motor and autonomic deficits. Study groups in-
cluded reaction-free patients, patients developing a RR,
patients with ENL, and a group of patients with unusual
clinical manifestations such as necrotizing ENL, mixed
RR-ENL reactions, polymorphic erythema, arthritis,
lymphadenopathy, orchitis, iritis, iridocyclitis, and reac-
tional hands and feet. Dermatologists with vast expertise
in leprosy diagnosis, treatment, and patients’ manage-
ment were in charge of the clinical diagnosis and follow-
up of leprosy reactions. Patients who developed leprosy
reactions or who had impaired nerve function received
appropriate treatment according to the guidelines of the
National Leprosy Control Program/Brazilian Ministry of
Health and remained in the study; RR, ENL, and associ-
ated clinical manifestations were registered in the case
report form (CRF).
ML Flow serological tests
The ML Flow test was performed, as previously de-
scribed elsewhere [10]. Briefly, 5 μl of whole blood and
running buffer were added to the sample well and visual
readings were performed 10 min later. Results were
recorded according to the scale of positivity: 0 and
0.5 = negative; 1 +, 2 +, 3 +, and 4 + = positive [10].
Statistical analyses
Leprosy patients were stratified into subgroups, as either
patients who had a reactional episode or reaction-free
patients. Episodes of RR and ENL were analyzed indi-
vidually or associated with neuritis. Statistical signifi-
cance was assessed using the chi-square (χ2) test to
compare the reactional and reaction-free groups. Results
were considered statistically significant when P-values
were <0.05. Descriptive analyses of the clinical, epi-
demiological, and laboratory variables and box plots
were performed using SPSS version 21 (IBM, New York,
USA). Receiver operating characteristic (ROC) curves
were determined with 95 % confidence intervals (CIs)
(using GraphPad Prism Software version 5, CA, USA).
Ethical considerations
The UMDT/CT-BR was performed under international
(Helsinki) and Brazilian research regulations regarding
human beings and was approved by regional ethics
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committees from all states involved in the study, as well
as by the National Commission for Ethics in Research
of the National Health Council/Ministry of Health
(February 17, 2006, protocol number 001/06). Written
informed consent was obtained from all patients prior
to their inclusion in the study. For patients aged below
18 years, written parental consent was obtained. Data
confidentiality was strictly guaranteed and all patients
knew they were free to leave the study and opt for
the R-MDT regimen outside of the study at any time
(ClinicalTrials.gov identifier: NCT00669643).
Results
U-MDT/CT-BR: Clinical and laboratory features of patients
at baseline and during follow-up
Of the 753 patients enrolled in the U-MDT/CT-BR,
80.5 % (606/753) were from Ceará and 19.5 % (147/753)
were from Amazonas. In terms of classification, 21 %
(158/753) were PB patients and 79.0 % (595/753) were
MB patients. The majority of PB patients were female
and reaction-free PB patients had the lowest median age
in PB group (34 years) (see Table 1). Most MB patients
were male, and MB patients who developed ENL had
the lowest median age in MB group (33 years).
In this cohort, 55.5 % (418/753) of patients had at least
one episode of a leprosy reaction during follow-up. The
distribution of the first leprosy episode according to R&J
groups is presented in Table 2. The most significant por-
tion of reactional patients had either BT or BL leprosy
(39 %; 294/753 and 31.1 %; 234/753, respectively). This
was followed by LL (16.5 %; 124/753), TT (6.4 %; 48/
753), and BB (5.6 %; 42/753). Only 1.5 % (11/753) had
indeterminate leprosy. The most prevalent type of reac-
tion was the RR, affecting 18.3 % (138/753) of patients
and occurring mainly in borderline patients (BT, BB, BL)
(136/138). Meanwhile, ENL was observed in 5.4 % (41/
753) of patients (all who had BL or LL). Neuritis alone
was observed in 19.8 % (149/753) of patients. Among
the patients who had a reaction, 21.5 % (90/418) had
reactions associated with other clinical manifestations,
such as neuritis, orchitis, arthritis, and lymphadenop-
athy. The majority of neuritis cases (59/149) and
reaction-free patients (190/335) had BT leprosy.
The distribution of reactions according to the WHO
operational classification is presented in Table 3. Leprosy
reactions were significantly more frequent in the MB
group (93.1 %; 389/418) compared with the PB group
(6.9 %; 29/418) (P < 0.001). Among MB patients, a sig-
nificant proportion had a RR (21.5 %; 128/595), while
6.9 % (41/595) had ENL. Almost one-third of the MB
patients (27.7 %; 165/595) had neuritis alone or neuritis
associated with RR or ENL, and 9.2 % (55/595) pre-
sented other unusual clinical manifestations such as
lymphadenopathy or polymorphic erythema. Out of the
PB cases who had a reaction, 6.3 % (10/158) developed a
RR and 12 % (19/158) had neuritis alone or neuritis as-
sociated with RR.
In this study group, 56.6 % (426/753) of patients were
positive for slit skin smears (mean BI = 3.39; SD = 1.49).
Patients with a positive BI smear (75.4 %; 321/426) were
more likely to develop a leprosy reaction as compared
with patients with a negative BI smear (29.7 %; 97/327)
(P < 0.001) (see Table 4). Out of the reactional patients
with a positive BI, 34.9 % (112/321) had a RR, 29.3 %
(94/321) had neuritis, and 12.8 % (41/321) developed
ENL. Almost half of the patients with a positive BI
(46.5 %; 198/426) developed leprosy reactions in the first
year following diagnosis.
Time of first episode of leprosy reaction
In this cohort, around 10 % patients had a leprosy reac-
tion at diagnosis (9.4 %, 71/753): 22.5 % (16/71) of these
patients had RR and 4.2 % (3/71) had ENL plus neuritis
(see Table 5). Thereafter, leprosy reactions were more
Table 1 Main characteristics of the 753 leprosy patients from UMDT/CT-BR study in PB and MB cases stratified according to the









PB reaction-free 129 86/43 34 (9-65) 11 I/ 42TT/ 75 BT/ 1BB 0 (0-1.75) 66/129
PB with RR 13 8/5 38 (6-60) 3 TT/ 7 BT/ 3 BB 0 (0-2.6) 6/13
PB with neuritis 16 10/6 39 (11-63) 3 TT/ 12BT/1BB 0 (0-0.75) 7/16
MB reaction-free 206 91/115 43 (8-65) 115 BT/ 9 BB/ 44 BL/ 38 LL 0 (0-6) 106/206
MB with RR 153 35/118 43 (7-65) 30 BT/ 17 BB/106 BL 2.75 (0-6) 78/153
MB with ENL 48 16/32 33 (8-62) 15 BL/ 33 LL 4.5 (0.5-5.6) 23/48
MB with others CM 55 17/38 45 (11-65) 9 BT/ 3 BB/ 26 BL/ 17 LL 4 (0-6) 30/55
MB with neuritis 133 42/91 36 (10-64) 47 BT/ 7 BB/ 43 BL/ 36 LL 4 (0-5.75) 53/133
PB Paucibacillary Leprosy, MB Multibacillary Leprosy, RR Reversal Reaction, ENL Erythema Nodosum Leprosum, CM clinical manifestations, n number, F female,
M male, R & J Ridley & Jopling Classification, BI Bacilloscopic Index, BCG Bacillus Calmette Guérin vaccine. PB and MB leprosy cases classification was based on the
number of skin lesions according to WHO operational classification system
Hungria et al. Infectious Diseases of Poverty  (2016) 5:110 Page 4 of 10
frequent in the first year after diagnosis, affecting 27.2 %
(205/753) of patients (RR: 34.6 %, 71/205; ENL: 4.4 %, 9/
205; neuritis: 37.6 %, 77/205), while 19 % (142/753) of
patients developed reactions during subsequent follow-
up (RR: 35.9 %, 51/142; ENL: 22.5 %, 32/142). The devel-
opment of ENL was more frequent in the first 12 months
after treatment compared to further follow-up (P = 0.02).
Overall, the development of leprosy reactions or other
clinical manifestations was more frequent in the first
year following diagnosis (27.2 %, 205/753 versus 19 %,
142/753; P = 0.003).
A similar frequency of leprosy reactions and other
clinical manifestations was observed among PB patients
being treated with U-MDT compared with PB patients
Table 2 Distribution of first episode of leprosy reactions and main clinical manifestations developed by patients stratified by R&J groups
I TT BT BB BL LL TOTAL (%)
Reactions 0 6 105 31 190 86 418 (55.5)
RR 0 2 28 16 92 0 138 (18.3)
ENL 0 0 0 0 13 28 41 (5.4)
Necrotising ENL 0 0 0 0 0 1 1 (0.1)
Lymphadenopathy 0 0 0 0 1 1 2 (0.2)
Reaction hand and foot 0 0 4 1 8 6 19 (2.5)
ENL + Polymorphic Erythema 0 0 0 0 1 0 1 (0.1)
ENL + Orchitis 0 0 0 0 0 1 1 (0.1)
ENL + Arthritis 0 0 0 0 0 1 1 (0.1)
ENL + Lymphadenopathy 0 0 0 0 1 1 2 (0.3)
ENL + reactional hand and foot 0 0 0 0 0 3 3 (0.4)
Mixed reaction / Type 1 + Type 2 0 0 0 1 6 1 8 (1.1)
Neuritis 0 3 59 8 43 36 149 (19.8)
Neuritis + RR 0 1 9 4 14 0 28 (3.7)
Neuritis + ENL 0 0 0 0 2 5 7 (0.9)
Neuritis + Mixed reaction 0 0 0 0 1 0 1 (0.1)
Neuritis + Arthritis 0 0 1 0 1 0 2 (0.3)
Neuritis + Orchitis 0 0 1 0 0 0 1 (0.1)
Neuritis + reactional hand and foot 0 0 3 1 7 1 12 (1.6)
Neuritis + ENL + polymorphic erythema 0 0 0 0 0 1 1 (0.1)
Reaction-free 11 42 190 10 44 38 335 (44.5)
Total 11 48 295 41 234 124 753 (100)
Table 3 Reactional status of UMDT/CT-BR leprosy patients







Reactions 29 (3.9) 389 (51.6) 418 (55.5)
RR 10 (1.3) 128 (17) 138 (18.3)
ENL 0 41 (5.4) 41 (5.4)
RR + Neu 3 (0.4) 25 (3.3) 28 (3.7)
ENL + Neu 0 7 (0.9) 7 (0.9)
Neuritis 16 (2.1) 133 (17.7) 149 (19.8)
Others 0 55 (7.3) 55 (7.3)
Reaction-free 129 (17.1) 206 (27.4) 335 (44.5)
Total 158 (21) 595 (79) 753 (100)
X2(6) = 118.97; p < 0.001
PB Paucibacillary Leprosy, MB Multibacillary Leprosy, RR Reversal Reaction, ENL
Erythema Nodosum Leprosum, Neu Neuritis, Others Other Manifestations
Table 4 Leprosy-reactional status of 753 patients enrolled at







Reactions 97 (12.9) 321 (42.6) 418 (55.5)
RR 26 (3.4) 112 (14.9) 138 (18.3)
ENL 0 41 (5.4) 41 (5.4)
RR + Neu 9 (1.2) 19 (2.5) 28 (3.7)
ENL + Neu 0 7 (0.9) 7 (0.9)
Neuritis 55 (7.3) 94 (12.5) 149 (19.8)
Others 7 (0.9) 48 (6.4) 55 (7.3)
Reaction-free 230 (30.5) 105 (14) 335 (44.5)
Total 327 (43.4) 426 (56.6) 753 (100)
X2(6) = 182.7; p < 0.001
BI Bacilloscopic Index, RR Reversal reaction, ENL Eritema Nodosum Leprosum,
Neu neuritis, Others others manifestations
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being treated with R-MDT (22.1 %, 17/77 versus 14.6 %,
12/82; P = 0.43). In addition, PB patients from both
treatment groups developed a RR (6/77 in the U-MDT
group and 4/82 in the R-MDT group). A similar fre-
quency of leprosy reactions was also seen among MB pa-
tients being treated with U-MDT compared with MB
patients being treated with R-MDT (66.7 %, 214/321 ver-
sus 64.1 %, 175/273; P = 0.61) (see Table 6).
ML Flow test results at baseline
At baseline, higher seropositivity in the ML Flow was re-
corded among patients with a positive BI as compared with
patients with a negative BI (86 %; 366/426 versus 29.1 %;
95/327) (P <0.001). The baseline serologic profile of pa-
tients evaluated by the ML Flow test showed higher posi-
tivity in patients who developed reactions (77 %; 322/418)
as compared with reaction-free patients (41.2 %; 138/335)
(P <0.001) (see Fig. 1) (see also Additional file 2: Table S1).
At baseline, the highest rate of ML Flow positivity and
the highest colour intensity of readings were recorded,
as expected, among patients with a positive BI from the
following categories: patients who developed ENL or
ENL associated with neuritis (92 %, 44/48; mean ML
Flow reading score: 2.7), followed by patients who pre-
sented with neuritis (86.2 %, 81/94; mean ML Flow
reading score: 2.6) and patients who developed a RR
(84.7 %, 111/131; mean ML Flow reading score: 2.4).
Reaction-free patients had the lowest positivity (81.9 %,
86/105; mean ML Flow reading score: 2.4), however,
differences among the groups were not statistically sig-
nificant (P = 0.45). Among the patients with a negative
BI, those who developed a RR or neuritis had a higher
ML Flow positivity rate and higher colour intensity in
test readings compared with reaction-free patients (RR:
45.7 %, 16/35, mean ML Flow reading score: 0.9; neur-
itis: 42.6 %, 23/54, mean ML Flow reading score: 0.8; re-
action-free: 22.7 %, 52/229, mean ML Flow reading score:
0.4) (P < 0.001) (see Figs. 1 and 2). Among the patients
who had a positive BI, the strength of the ML Flow signal
was similar in patients who had a reaction (ENL, RR, or
neuritis) and reaction-free patients (P > 0.05), while among
the patients who had a negative BI, a higher signal
strength was observed in patients who developed RR as
compared with the reaction-free patients (P = 0.003)
(see Fig. 2).
The accuracy of the ML Flow test at baseline to predict
whether a patient will develop leprosy reactions was ana-
lyzed using the ROC curve. For patients who had a nega-
tive BI and developed a RR during follow-up or who did
not have a reaction, the area under the curve was <0.7.
Establishing a specificity of 90 % (95 % CI: 85–93 %), the
sensitivity was 28 % (95 % CI: 14–46 %) for a reading score
of ≥2. Similar results were observed in patients who
had a positive BI and developed ENL or RR (see
Additional file 3: Figure S1).
Discussion
For many years, leprosy patients were treated with dap-
sone monotherapy, and the development of ENL was re-
ported in half of LL patients and in one-quarter of BL
patients [24]. The introduction of MDT in the 1980s re-
duced the frequency and the severity of ENL, probably as
a result of the anti-inflammatory activity of clofazimine
Table 5 Time of presentation of leprosy reaction among UMDT/CT-BR patients according to type of reaction
At diagnosis
N (%)
In the 1st year after diagnosis
N (%)






RR 16 (22.5) 71 (34.6) 51 (35.9) NA 138 (18.3)
ENL 0 9 (4.4) 32 (22.5) NA 41 (5.4)
RR + Neu 6 (8.5) 15 (7.3) 7 (4.9) NA 28 (3.7)
ENL + Neu 3 (4.2) 3 (1.5) 1 (0.7) NA 7 (0.9)
Neuritis 43 (60.6) 77 (37.6) 29 (20.4) NA 149 (19.8)
Others 3 (4.2) 30 (14.6) 22 (15.5) NA 55 (7.3)
Total 71 (100) 205 (100) 142 (100) 335 (100) 753 (100)
RR Reversal reaction, ENL Eritema Nodosum Leprosum, Neu neuritis, Others others manifestations
Table 6 Leprosy reactions among patients enrolled at UMDT/











Reactions 17 (22.1) 12 (14.6) 214 (66.7) 175 (64.1) 418 (55.5)
RR 6 (7.8) 4 (4.9) 69 (21.5) 59 (21.6) 138 (18.3)
ENL 0 0 20 (6.2) 21 (7.7) 41 (5.4)
RR + Neu 1 (1.3) 2 (2.4) 15 (4.7) 10 (3.7) 28 (3.7)
ENL + Neu 0 0 5 (1.6) 2 (0.7) 7 (0.9)
Neuritis 10 (13) 6 (7.3) 79 (24.6) 54 (19.8) 149 (19.8)
Others 0 0 26 (8.1) 29 (10.6) 55 (7.3)
Reaction-free 60 (77.9) 70 (85.4) 107 (33.3) 98 (35.9) 335 (44.5)
Total 77 (100) 82 (100) 321 (100) 273 (100) 753 (100)
For the statistical analysis of PB patients were excluded ENL and ENL + neuritis.
RR and RR + neuritis were grouped
RR Reversal reaction, ENL Eritema Nodosum Leprosum, Neu neuritis, Others
others manifestations
PB – x2(2) = 1.69; p = 0.43; MB – x
2
(6) = 0.61; p = 0.61
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that was included in the treatment regimen [25]. However,
previous data from the U-MDT cohort showed that there
was no statistical difference in the frequency of leprosy re-
actions among MB patients receiving R-MDT or U-MDT,
indicating that six or 12 months of clofazimine treatment
does not result in the prevention of leprosy reactions [26].
In the U-MDT/CT-BR, until 2014, 780 930 person-days,
i.e. 2 139.5 person-years, with a maximum of 6.66 years of
follow-up were evaluated [9]. In the current study, a com-
parable frequency of leprosy reactions and other clinical
manifestations was observed in PB patients being treated
with U-MDT or R-MDT. Findings from a previous report
together with findings from the current investigation
indicate that whether patients receive U-MDT or R-MDT
does not have any impact on the incidence of leprosy reac-
tions and other clinical manifestations such as neuritis.
In this cohort of leprosy patients, composed mainly of
MB patients (~80 %), more than half developed at least
one episode of a leprosy reaction. Moreover, the great
majority of patients who developed reactions were MB
patients with high BIs, and these variables have been
previously associated with a high probability of develop-
ing leprosy reactions [2, 27, 28]. Our results confirm that
MB patients have a higher risk of developing leprosy re-
actions as compared with PB patients. In addition, the
study confirms that the most common reaction in both
Fig. 1 ML Flow test results stratified according to BI and reaction type. Legend: ML Flow result was missing for one patient
Fig. 2 Intensity of positive ML Flow tests, according to BI and type of reaction
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MB and PB patients is RR, and ENL occurs only in MB
patients. While most MB patients developed reactions,
the majority of PB patients remained reaction-free.
Overall, more than half of the patients had a positive BI
and reactions were more frequent in these patients as
compared with patients who had a negative BI. The de-
velopment of reactions was more common in the first
year of follow-up compared to subsequent years. Our
results are in accordance with other studies, which
showed the predominance of RR over ENL and the
higher incidence of reactions in MB patients with a
positive BI as compared with patients with a negative
BI [29, 30].
In this cohort, RRs were seen mainly in BL MB pa-
tients, a finding which is consistent with other studies
[2, 14, 31]. The majority of patients who developed ENL
had LL and high BIs. Other studies have reported that
ENL is more often seen in LL patients than in BL pa-
tients [32, 33] and a higher BI is a known risk factor for
developing ENL [34, 35]. Interestingly, MB patients who
developed ENL were younger than reaction-free MB pa-
tients. Accordingly, a study that evaluated risk factors
for developing ENL showed that patients older than
40 years were less likely to develop ENL [34]. Another
study showed that patients whose first leprosy symptom
occurred during adolescence had a greater chance of de-
veloping ENL than patients whose onset of leprosy oc-
curred after adolescence [36]. In this study, PB patients
who developed RR were older than reaction free-PB pa-
tients. Other studies have shown that older age was an
important risk factor for developing both RR at diagno-
sis and developing sequelae after treatment [37, 38].
During MDT, bacillary death occurs resulting in a
massive release of mycobacterial antigens favoring the
formation of immune complexes, mainly among MB pa-
tients, and immune complexes are considered to play a
role in the pathophysiology of leprosy reactions [39–42].
In this study, reactions were more frequent during the
course of MDT, as previously reported [2, 27, 43]. How-
ever, patients mainly developed ENL during follow-up.
The results of this study underline the importance of
alerting patients about the possible development of reac-
tions before, during, and even years after the conclusion
of MDT, since reactions require immediate assistance
and specific treatment to avoid irreversible nerve dam-
age. Overall, neuritis was a common clinical manifest-
ation that occurred in all clinical forms of leprosy, with
higher frequencies observed in BT and BL forms. Similar
to previously reported data, isolated neuritis with no
other dermatological or clinical symptom was present in
20 % of cases, while less than half of the neuritis cases
were associated with a reaction [44].
In this study, baseline positivity determined using the
ML Flow test was associated with MB disease, a positive
BI, and the development of reactions during follow-up,
mainly ENL. Bacillary load is known to directly correlate
with antibody levels and with the development of leprosy
reactions [2, 16, 27, 28]. Moreover, antibodies, which are
abundant in MB patients, probably play a role in the
pathophysiology of ENL [15–17, 39]. However, little, if
anything, is known about the role of antibodies in the
development of RRs and other clinical manifestations
such as neuritis. In this study, at baseline, patients
with a negative BI who developed neuritis and RRs
during follow-up had higher ML Flow positivity with a
higher colour intensity compared with reaction-free
patients who had a negative BI. Further studies on the
immunopathogenesis of RRs are needed in order to
clarify whether antibodies play a role in the develop-
ment of RRs.
Our ROC analysis showed that the results of the ML
Flow test at baseline had limited sensitivity and specificity
to predict whether patients will develop leprosy reactions
during follow-up (see Additional file 3: Figure S1).
Additionally, high ML Flow seropositivity was not always
associated with leprosy reactions and other clinical mani-
festations, as high positivity was also observed in reaction-
free patients.
Conclusions
In the U-MDT/CT-BR, until 2014, 780 930 person-days,
i.e. 2 139.5 person-years, with a maximum of 6.66 years
of follow-up were evaluated, in this period MB and PB
patients receiving R-MDT or U-MDT showed similar
frequencies of RR, ENL and other clinical manifesta-
tions. Moreover, our data confirm that MB patients with
a positive BI are more likely to develop leprosy reactions,
and overall RRs are more common than ENL. Leprosy
reactions were more likely to happen in the first year
post-MDT, suggesting that special emphasis needs to be
placed on clinical monitoring during this period. A sig-
nificant proportion of patients presented neuritis alone
or neuritis associated with reactions. ML Flow test re-
sults at baseline showed limited sensitivity and specificity
for predicting whether patients will develop leprosy reac-
tions during follow-up. Positive ML Flow tests were as-
sociated with MB disease, having a positive BI, and
developing reactions, particularly ENL. As well as that,
RR and neuritis were also reported in patients with a
negative BI, and these patients had more positive ML
Flow test results compared with the reaction-free pa-
tients who had a negative BI. Therefore ML Flow test re-
sults at baseline cannot be used as a predictive marker
for leprosy reactions. Further studies to investigate other
quantitative serological markers, besides anti PGL-I re-
sponse, may help us to further understand the role of
serology as a predictive tool for leprosy reactions.
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